<DOC>
	<DOC>NCT00309023</DOC>
	<brief_summary>This is a Phase I/II, ascending, multi-dose study of BMS-663513, an agonistic anti-CD137 monoclonal antibody, administered every three weeks to patients with metastatic or locally advanced solid tumors.</brief_summary>
	<brief_title>Study of BMS-663513 in Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Eastern Cooperative Oncology Group (ECOG) score of 01. Measurable disease. Absolute neutrophil count (ANC) &gt;= 1,500 cells/mm3 Platelet count &gt;= 100K cells/mm3 Hemoglobin &gt;= 9.0 g/dL Total bilirubin &lt;= 1.5 x IULN Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase &lt;= 2.5 x institutional upper limit of normal (IULN) Patients with advanced solid malignancies must have melanoma, renal or ovarian carcinoma History of autoimmune diseases. Condition requiring the continued use of systemic or topical steroids or the use of immunosuppressive agents. Active/symptomatic brain metastasis. History of hepatitis B or C. Concurrent malignancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>